TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03090984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA (BKU)
Description: At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS (Phylter)
Description: At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69ST (Evodial)
Description: At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
Study: NCT00274209

Intervention type: PROCEDURE
Intervention: Chromoendoscopy with magnification
Description: A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
Study: NCT00800059

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
Study: NCT02473978

Intervention type: DEVICE
Intervention: INVOS Cerebral Oximetry
Description: Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.

Intervention type: DEVICE
Intervention: INVOS Cerebral Oximetry
Description: Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
Study: NCT04050488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Study: NCT03089528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Description: the trachea will be intubated with a videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laringoscope
Description: the trachea will be intubated with a laringoscope
Study: NCT03701828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weight loss surgery
Description: All surgery types will be included. However, only participants scheduled for surgery with collaborating surgeons will be included. Surgery is not provided by study team.
Study: NCT02226328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and Fentanyl sedation
Study: NCT02907528

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone
Description: Furcation defect regenerated with bone graft material

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: Furcation defect regenerated with EMD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD
Description: Furcation defect regenerated with EMD
Study: NCT05504538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
Description: arthroscopic fixation of Acute acromioclavicular joint injury using tight rope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tight rope
Description: Adjustable button device from Arthrex Naples USA
Study: NCT02388815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed.
Study: NCT02280746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten challenge
Description: Intervention will be continued for at least 6 months
Study: NCT01296945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk
Description: Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper
Description: Participants will receive a paper handout with nutrition educational information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk PLUS paper
Description: Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
Study: NCT02512354

Intervention type: OTHER
Intervention: Sample of a fragment of fetal tissue

Intervention type: OTHER
Intervention: Parent's blood samples
Study: NCT01832805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation.
Description: In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
Study: NCT04592354

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxaloacetate Medical Food/Dietary Supplement
Description: 500 mg Anhydrous Enol-Oxaloacetate BID

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxaloacetate Medical Food/Dietary Supplement
Description: 500 mg Anhydrous Enol-Oxaloacetate BID
Study: NCT00440596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: 8 weeks group MBSR
Study: NCT01296945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk PLUS web
Description: Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
Study: NCT02940418

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adipose mesenchymal cells with bone marrow mononuclear cells
Description: Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
Study: NCT02701127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03299426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Description: Single 0.5-ml intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal A Conjugate Vaccine (MCV-A)
Description: Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
Study: NCT01280032

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
Study: NCT04236661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chilipad
Description: Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
Study: NCT00675428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Study: NCT01248052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally
Study: NCT02610543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
Study: NCT01902810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization
Study: NCT00440596

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: 8 weeks PMR in group format
Study: NCT06104696

Intervention type: PROCEDURE
Intervention: Functional geriatric assessment
Description: Examination of physical and mental status using standardized tests.
Study: NCT01902810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth given daily throughout hospitalization
Study: NCT03008265

Intervention type: OTHER
Intervention: Postoperative fascial dehiscence
Study: NCT03209141

Intervention type: DIAGNOSTIC_TEST
Intervention: Diastolic function evaluation
Description: Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)

Intervention type: DIAGNOSTIC_TEST
Intervention: Diastolic function evaluation
Description: Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
Study: NCT04115475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study: NCT06104696

Intervention type: PROCEDURE
Intervention: Functional geriatric assessment
Description: Examination of physical and mental status using standardized tests.

Intervention type: PROCEDURE
Intervention: Functional geriatric assessment
Description: Examination of physical and mental status using standardized tests.
Study: NCT04115475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study: NCT00771017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX prostate cancer vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given intramuscularly
Study: NCT04484974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan snack
Description: Under this condition, each participant will consume a mid morning snack of pecans followed by an ad libitum lunch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tortilla chip snack
Description: Under this condition, each participant will consume a mid morning snack consisting of an iso-caloric (equal to the pecan snack) snack of tortilla chips followed by an ad libitum lunch.
Study: NCT02487472

Intervention type: OTHER
Intervention: Data collection
Description: Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
Study: NCT03885102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise intervention
Description: 50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care with no exercise intervention or health literacy counselling
Study: NCT00132002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03141489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tubefeeding
Description: NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tubefeeding
Description: NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
Study: NCT01787474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Description: Given IV
Study: NCT03182179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: Ondansetron is taken orally BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: Ondansetron is taken orally BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken orally BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken orally BD
Study: NCT04210895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger powder footbath
Description: 40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm water only footbath
Description: 40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
Study: NCT03734237

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg based influenza vaccines
Description: Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant influenza vaccines
Description: Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cell-culture based influenza vaccines
Description: Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
Study: NCT02093689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 2 Placebo
Description: Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
Study: NCT05728632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol, capsule, 5 mg once daily, for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsule, once daily, for 12 months
Study: NCT01679132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO System and Medical Management
Description: Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators.
Study: NCT02229240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching albiglutide placebo
Description: Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
Study: NCT01579474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 high dose
Description: BI 201335 high dose with PegIFN/RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 low dose
Description: BI 201335 low dose with PegIFN/RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 high dose
Description: BI 201335 high dose with PegIFN/RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 high dose
Description: BI 201335 high dose with PegIFN/RBV
Study: NCT03182608

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasound assessment
Description: An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasound assessment
Description: An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
Study: NCT03204591

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01567306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac Depot
Description: Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Study: NCT04296357

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.